Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-26-084621
Filing Date
2026-07-17
Accepted
2026-07-17 16:05:42
Documents
15

Document Format Files

Seq Description Document Type Size
1 FORM S-3 tm2619649d3_s3.htm S-3 202384
2 EXHIBIT 5.1 tm2619649d3_ex5-1.htm EX-5.1 10294
3 EXHIBIT 23.1 tm2619649d3_ex23-1.htm EX-23.1 2128
4 EX-FILING FEES tm2619649d3_ex-filingfees.htm   iXBRL EX-FILING FEES 25419
5 GRAPHIC tm2619649d3_ex5-1img001.jpg GRAPHIC 9780
6 GRAPHIC tm2619649d1_drsimg001.jpg GRAPHIC 5095
  Complete submission text file 0001104659-26-084621.txt   384642

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2619649d3_ex-filingfees_htm.xml XML 5077
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: S-3 | Act: 33 | File No.: 333-297532 | Film No.: 261183768
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)